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Abstract
A 60-year-old male was diagnosed with T3, N3, M1b epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma.
Five months later he developed signiﬁcant headaches, weakness and numbness of the left leg, and unsteadiness of gait.
Magnetic resonance imaging (MRI) brain demonstrated subtle gyral enhancement indicative of early leptomeningeal
inﬁltration. He was commenced on second-line erlotinib which improved his lower limb symptoms. Three months later he
developed increased urinary frequency and redeveloped leg symptoms. MRI brain showed improvement in the gyral
enhancement. Four weeks later, the patient developed new onset confusion and decrease in mobility. Examination of the
cerebrospinal ﬂuid (CSF) demonstrated leptomeningeal carcinomatosis. This case demonstrates radiological and clinical
response of leptomeningeal disease to erlotinib in EGFR mutant lung cancer with subsequent clinical relapse despite continued
radiological resolution of leptomeningeal disease. This suggests that CSF examination should be considered when monitoring
leptomeningeal disease response following treatment as the disease can be undetectable on repeat radiological imaging.
INTRODUCTION
Leptomeningeal carcinomatosis is the inﬁltration of the lepto-
meninges by malignant cells. Without treatment the median
survival is 4–6 weeks and death occurs from progressive neuro-
logical dysfunction [1]. Approximately 9% of epidermal growth
factor receptor (EGFR) mutant non-small cell lung cancer
(NSCLC) patients proceed to develop leptomeningeal carcin-
omatosis [2].
Previous case reports have demonstrated that erlotinib, an
EGFR tyrosine kinase inhibitor (TKI), can induce clinical and
radiological response in EGFR mutant NSCLC patients with
leptomeningeal carcinomatosis [2, 3].
CASE REPORT
A 60-year-old male with no signiﬁcant medical history was diag-
nosed with T3, N3, M1b lung adenocarcinoma in May 2015. He ini-
tially presented to his General Practitioner with an unresolving
cough. Investigations revealed the primary lung tumour and lytic
bone metastases, with loss in height of L4. Histology from
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bronchoscopy conﬁrmed a lung adenocarcinoma with an EGFR
exon 19 deletion mutation. He received palliative radiotherapy to
L3-L5 vertebrae, and four cycles of Cisplatin/Pemetrexed
chemotherapy.
In October 2015, he developed signiﬁcant headaches, weak-
ness and numbness of the left leg, and unsteadiness of
gait. Magnetic resonance imaging (MRI) brain demonstrated
multiple skull metastases and subtle gyral enhancement indi-
cative of early leptomeningeal inﬁltration (Fig. 1a). MRI spine
demonstrated multifocal marrow deposits with new vertebral
collapse in T6 but no evidence of signiﬁcant cord compression.
He received radiotherapy to base of skull and T5–T7 vertebra. In
view of his EGFR mutation status, he was commenced on
second-line treatment with erlotinib at standard oral dosing.
His leg weakness and unsteadiness improved.
In January 2016 he developed increased urinary frequency
with a feeling of incomplete emptying of the bladder. His pros-
tate was not enlarged, prostate speciﬁc antigen (PSA) was not
raised and urine cultures were negative. A bladder ultrasound
demonstrated a large residual with no evidence of outﬂow
obstruction. During this period the patient redeveloped leg
weakness and unsteadiness of gait. MRI spine demonstrated
resolution of the soft tissue at T6 level, and MRI brain showed
an improvement in the gyral enhancement (Fig. 1b). A com-
puted tomography thorax/abdomen/pelvis performed at the
same time demonstrated minor interval disease response.
Four weeks later, the patient was admitted to hospital as an
emergency with new onset confusion and a decrease in mobil-
ity. He was found to be in urinary retention and a catheter was
inserted. Left lower limb weakness was demonstrated. Hip ﬂex-
ors and knee extensors were 4/5 on the Medical Research
Council (MRC) power scale, ankle dorsiﬂexion 1/5 and great toe
extension 3/5. Abbreviated Mental Test Score ﬂuctuated
between 7/10 and 10/10 on consecutive days. MRI spine showed
no evidence of cord compression, and MRI brain did not dem-
onstrate evidence of radiological progression (Fig. 1c). Lumbar
puncture and examination of the cerebrospinal ﬂuid (CSF),
however, revealed atypical epithelioid cells likely to represent
malignant cells, consistent with intrathecal dissemination of
the known metastatic lung adenocarcinoma (Fig. 2). The
patient died 2 weeks later.
DISCUSSION
Erlotinib is an EGFR TKI that has been demonstrated to cross
the blood brain barrier (BBB) and accumulates in the CSF at
concentrations greater than its IC50 when taken at standard
oral doses [4, 5]. This drug is able to permeate across the BBB
due to its low molecular weight and the disruption of the integ-
rity of the BBB during the metastatic process [6].
The use of erlotinib has previously been shown to induce
clinical and radiological response in EGFR NSCLC patients with
leptomeningeal carcinomatosis [2, 3] with an increase in overall
survival and performance status following treatment [7]. EGFR
TKI treatment naïve EGFR mutant leptomeningeal disease
responds to treatment with an EGFR TKI and continued radio-
logical response is associated with prolonged survival.
However, the median time to progression or symptom deterior-
ation in patients with leptomeningeal disease receiving EGFR
TKIs remains short, at 2.2 months [2]. Ascertaining the cause of
death in patients with leptomeningeal disease can be difﬁcult
as they often have concomitant refractory progressive systemic
disease [8].
MRI brain imaging has a sensitivity of approximately 70%
for the detection of leptomeningeal disease [9] and CSF examin-
ation is the gold standard for diagnosing leptomeningeal car-
cinomatosis [10]. However, when it comes to assessing
leptomeningeal disease response following treatment, methods
for assessment of outcome and response criteria have not been
standardised. Assessment methods that have been looked at
include MRI imaging which may not be sufﬁciently sensitive
and lacks a consensus criteria for assessing response, CSF
examination which is invasive and may require repeat sam-
pling, and clinical examination, which can be variable and sub-
jective [8].
Here we demonstrate a case of an EGFR mutant lung
adenocarcinoma patient with leptomeningeal carcinomatosis
who initially responded symptomatically and radiologically
to second-line erlotinib. Despite demonstrating sustained
radiological response to erlotinib with regards to his systemic
and leptomeningeal disease, he subsequently relapsed with
symptoms suggestive of leptomeningeal carcinomatosis.
Recurrence of leptomeningeal disease was proven on CSF
examination. Although it was unfortunate that his leptomen-
ingeal disease had recurred, the conﬁrmation of the diagno-
sis provided the patient and his family the opportunity to
plan for end of life care and related issues, especially as his
radiological imaging gave the impression that he was still
responding to treatment. His duration of survival following
erlotinib treatment was comparable to that in previous
reports [2].
Previous studies have focused on radiological response to
EGFR TKIs as their outcome measure. However, our report sug-
gests that response monitoring of leptomeningeal disease fol-
lowing erlotinib treatment cannot be reliably measured by
radiological criteria alone. Clinical history and examination,
and CSF cytology needs to be evaluated especially as there is a
lack of consensus regarding assessment methods and
Figure 1: Coronal T1W post gadolinium MRI brain images. (a) Prior to erlotinib
treatment demonstrating leptomeningeal enhancement, most notable in the paraf-
alcine region and overlying the temporal lobes. (b) After 12 weeks of erlotinib treat-
ment. There is a decrease in leptomeningeal enhancement. (c) After 16 weeks of
erlotinib treatment. There is no progression in leptomeningeal enhancement
Figure 2: Photographs of CSF cytospins stained with MGG (May Gruenwald
Giemsa) stain. The low power image on the left shows scattered tumour cells
against a background of mononuclear cells. The high power image on the right
shows a tumour cell in more detail. Note the large prominent nucleolus, the
generally large size of the cell, the deep blue cytoplasm and well-deﬁned cyto-
plasmic border
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outcome criteria for monitoring leptomeningeal disease
response. CSF examination should be considered in all
patients with EGFR mutant lung cancer when monitoring
leptomeningeal disease response following treatment as the
disease can be undetectable on repeat radiological imaging.
Accurate diagnosis and response monitoring helps to inform
prognosis and this information can be highly valued by
patients and their next of kin.
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